Journal of Oncology Pharmacy Practice This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer
Conclusions Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with BC and these changes are more profound in pre-menopausal patients. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - December 15, 2015 Category: Cancer & Oncology Authors: Bicakli, D. H., Varol, U., Degirmenci, M., Tunali, D., Cakar, B., Durusoy, R., Karaca, B., Ali Sanli, U., Uslu, R. Tags: Original Articles Source Type: research

Environmental contamination by cyclophosphamide preparation: Comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo
Conclusions Compared to outcomes of other studies, our results underline good manufacturing procedures in this pharmacy with low contamination for both techniques (BSC and APOTECAchemo). Comparison of both preparation procedures validated that contamination of infusion bags was much lower by using the robotic system. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - December 15, 2015 Category: Cancer & Oncology Authors: Schierl, R., Masini, C., Groeneveld, S., Fischer, E., Böhlandt, A., Rosini, V., Paolucci, D. Tags: Original Articles Source Type: research

Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags
Conclusion The extended physico-chemical stability of carboplatin prepared in sodium chloride reported herein permits advance preparation of these admixtures, facilitating pharmacy utility and operations. Since no antibacterial preservative is contained within these carboplatin solutions, we recommend storage, when prepared under specified aseptic conditions, no greater than 24 h at room temperature or three days under refrigeration. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - December 15, 2015 Category: Cancer & Oncology Authors: Myers, A. L., Zhang, Y.-P., Kawedia, J. D., Trinh, V. A., Tran, H., Smith, J. A., Kramer, M. A. Tags: Original Articles Source Type: research

Compliance with National Comprehensive Cancer Network anti-emesis guidelines in a Community Hospital Cancer Center
Conclusion Overall compliance with guidelines is acceptable. Patients in the moderate risk category are most likely to receive appropriate anti-emetic prophylaxis. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - December 15, 2015 Category: Cancer & Oncology Authors: Daniel, D., Waddell, A. Tags: Original Articles Source Type: research

Physical and chemical stability of proflavine contrast agent solutions for early detection of oral cancer
Conclusion Proflavine solutions at concentration of 0.01% were chemically and physically stable for at least 12 months under refrigeration. The solution was chemically stable for six months when stored at room temperature. We recommend long-term storage of proflavine solutions under refrigeration prior to diagnostic procedure. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - December 15, 2015 Category: Cancer & Oncology Authors: Kawedia, J. D., Zhang, Y.-P., Myers, A. L., Richards-Kortum, R. R., Kramer, M. A., Gillenwater, A. M., Culotta, K. S. Tags: Original Articles Source Type: research

Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator
Conclusion Surface contamination from cytotoxic infusion preparation in a pharmaceutical isolator was significant and could transmit cytotoxic residues to patient and public areas via infusion surfaces. The frequency and amount of contamination were reduced by the CSDTD. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - December 15, 2015 Category: Cancer & Oncology Authors: Vyas, N., Turner, A., Clark, J., Sewell, G. Tags: Original Articles Source Type: research

Assessment of final product dosing accuracy when using volumetric technique in the preparation of chemotherapy
Conclusion While the mean value of volumetric measurements is within the generally understood acceptable range for dispensing chemotherapy, the range of measurements is highly variable. Future studies are warranted to better understand the reasons behind the variation and to evaluate the impact of workflow changes on improving final product accuracy. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - December 15, 2015 Category: Cancer & Oncology Authors: Poppe, L. B., Savage, S. W., Eckel, S. F. Tags: Original Articles Source Type: research

Practical considerations in the use of intravenous tacrolimus in hematopoietic stem cell transplantation patients
(Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Bauters, T., Rayner, P., Therrien, R., Lancker, S. V., Bordon, V., Cordroch, M. L., Dhooge, C., Benoit, Y., Vandenbroucke, J. Tags: Letter to the Editor Source Type: research

Delayed hypersensitivity reaction related to the use of pegfilgrastim
We present a patient with early breast cancer who developed a rash more than a week after the use of pegfilgrastim. Clinicians must be aware of the possibility of a delayed hypersensitivity reaction as the application of this drug is increasing and an adverse event can result in delay of chemotherapy treatment. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Dadla, A., Tannenbaum, S., Yates, B., Holle, L. Tags: Case Reports Source Type: research

Pyoderma gangrenosum due to lenalidomide use for multiple myeloma
We report herein occurrence of pyoderma gangrenosum involving bilateral knees in a patient with multiple myeloma responding to lenalidomide therapy. Previous papers claimed usefulness of thalidomide and its newer derivatives for the therapy of this neutrophilic dermatosis. Occurrence of pyoderma gangrenosum in a myeloma patient responding to lenalidomide would argue against its effectiveness in treating this skin condition. Moreover, the clinical setting suggested that lenalidomide either induced or contributed to the occurrence of pyoderma gangrenosum in our patient. If our hypothesis is correct, we expect more reports of...
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Dasanu, C. A., Bockorny, B., Alexandrescu, D. T. Tags: Case Reports Source Type: research

Is there any cumulative dose for trastuzumab?
Trastuzumab is one of the most important agents that target human epidermal growth factor receptor 2, but its cardiotoxic effect limits to use it. The mechanism of cardiac dysfunction-related trastuzumab is still unclear. In literature, there is no definite information about the cumulative dose of trastuzumab for cardiotoxicity. In presented case, we reported a breast cancer patient who has been receiving long-term trastuzumab. We have not found any cardiac problems for duration of over four years. According to our case and literature review, we may say that trastuzumab is safely used with periodically echocardiographic co...
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Mutlu, H., Coskun, H. S. Tags: Case Reports Source Type: research

Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
Significant enthusiasm currently exists for new immunotherapeutic strategies: blocking the interaction between programmed death-1 receptor on T-cells and programmed death-ligand 1 on tumor cells to boost immune system stimulation to fight cancer. Immunomodulation with the antiprogrammed death-1/programmed death-ligand 1 monoclonal antibodies has shown to mediate tumor shrinkage and extend overall survival from several pivotal phase I/II studies in melanoma, renal cell carcinoma, and non-small cell lung cancer. This has prompted multiple large ongoing phase III trials with the expectation for fast-track FDA approvals to sat...
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Lu, J., Lee-Gabel, L., Nadeau, M. C., Ferencz, T. M., Soefje, S. A. Tags: Review Articles Source Type: research

Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects!
We report herein the first such case and believe that further studies confirming this association are warranted. We further review the existing posterior reversible encephalopathy syndrome cases associated with targeted therapies in the scientific literature. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Khurana, A., Dasanu, C. A. Tags: Review Articles Source Type: research

Targeting the mammalian target of rapamycin pathway with everolimus: Implications for the management of metastatic breast cancer
The inhibitors of mammalian target of rapamycin (mTOR) have documented antitumor activity via disruption of various signaling pathways leading to impaired cellular growth, proliferation, and survival. In preclinical studies, mTOR inhibitors use in combination with hormonal therapy has shown promising results in overcoming endocrine resistance in breast cancer cells. The role of everolimus in breast cancer was established in the Breast Cancer Trial of Oral Everolimus-2 (BOLERO-2) trial in combination with exemestane for patients with advanced metastatic hormone receptor-positive (HR+) breast cancer, who relapsed after initi...
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Ng, V. C., Johnson, J. J., Cuellar, S. Tags: Review Articles Source Type: research

Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
Conclusions Further prospective studies are warranted to elucidate which weight is most likely to achieve goal AUC and subsequent optimal patient outcomes. (Source: Journal of Oncology Pharmacy Practice)
Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Clemmons, A. B., Evans, S., DeRemer, D. L., Awan, F. T. Tags: Original Articles Source Type: research